Zanubrutinib in patients with treatment‐naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded‐access study of 50 patients in the United States

Documenti analoghi

• Zanubrutinib in patients with treatment‐naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded‐access study of 50 patients in the United States
  di: Jorge J Castillo, et al.
  Pubblicazione: (2023-02-01)
• Zanubrutinib-Induced Acneiform Rash in a Patient With Waldenstrom’s Macroglobulinemia
  di: Silvia Robuffo, et al.
  Pubblicazione: (2026-01-01)
• Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia
  di: Javier Muñoz, et al.
  Pubblicazione: (2022-10-01)
• Pathophysiology of Waldenström’s macroglobulinemia
  di: Marvin J. Stone, et al.
  Pubblicazione: (2010-03-01)
• P110 | ZANUBRUTINIB IN WALDENSTROM MACROGLOBULINEMIA. REPORT ON THE EXPERIENCE OF THE CAMPANIA GROUP ON CLL/WM: THE DIAGNOSTIC AND INTEGRATED DIRECTION FOR OPTIMIZED CAMPANIA NETWORKING IN WALDENSTROM DISEASE (DIDONE) PROJECT.
  di: G. D'arena, et al.
  Pubblicazione: (2025-09-01)